BTG is to regain ahead of schedule the full US marketing rights to the antivenom CroFab (crotalidae polyvalent immune fab (ovine)) and the overdose product DigiFab (digoxin immune fab (ovine)) from Nycomed.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?